Correction
==========

In the article \[[@B1]\] there were errors in Tables three, four, five, six and seven. The incorrect values were produced due to typographical errors during translation stage. These errors affect neither the published discussion nor the conclusions of the paper. However, a few changes to the results section are detailed here.

In the Abstract, under \"Results\" the first two sentences read
===============================================================

\"The positive rate of EGFR protein in NSCLC tumor cells was 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous tissues (p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.04).\"

But should have been:

\"The positive rate of EGFR protein in NSCLC tumor cells was 46%, which was significantly higher than its expression in normal lung (p = 0.034) and paracancerous tissues (p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.006).\"

In the main \"Results\" section of the article
==============================================

The sentence under the heading \"**EGFR protein expression**\" read: \"The positive rate of EGFR protein in NSCLC tumor cells were 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous (p = 0.020)\"

Which should have been:

\"The positive rate of EGFR protein in NSCLC tumor cells were 46%, which was significantly higher than its expression in normal lung (p = 0.034) and paracancerous (p = 0.020)\"

Under the heading \"**Correlation between EGFR expression and clinical features**\" The second sentence read: \"It shows that the difference of EGFR expression was only significant between the nodal positive and negative subgroups (56.4% vs.10%, p = 0.04).\"

But the passage should have been \"The expression of EGFR in different subgroups were compared and summarized in Table three. It shows that the difference of EGFR expression was only significant between the nodal positive and negative subgroups (56.4% vs. 9.1%, p = 0.006). There is no significant difference between age (60 vs. under 60 ys), gender, adeno- vs. non-adenocarcinoma, the differentiation of tumor, and staging.\"

This is the correct table three (table [1](#T1){ref-type="table"}).

###### 

(corrected table 3). EGFR expression and clinical characteristics

  Clinical features                  EGFR   Positive expression rate   *P*value   
  ---------------------------------- ------ -------------------------- ---------- ---------
  Ages                                                                            0.448
  \< 60                              18     14                         43.80%     
  ≥60                                9      9                          50%        
  Sex                                                                             0.445
  Male                               16     15                         48.40%     
  Female                             11     8                          42.10%     
  Pathologic type                                                                 0.543
  Squamous carcinoma                 13     8                          38.10%     
  Adencarcinoma                      13     13                         50.0%      
  Mixed type                         1      2                          66.70%     
  Tumor length                                                                    0.535
  ≤3 cm                              9      7                          43.80%     
  \> 3 cm                            18     16                         47.10%     
  Level of Differentiation                                                        0.474
  Poor Differentiated                6      4                          40%        
  Moderate and Well Differentiated   21     19                         47.50%     
  TNM Stage                                                                       0.194
  I-II                               10     5                          33.30%     
  III-IV                             17     18                         51.40%     
  Lymph node                                                                      0.006\*
  N0                                 10     1                          9.10%      
  N1-3                               17     22                         56.40%     

\*P \< 0.05

Correct tables four (table [2](#T2){ref-type="table"}), five (table [3](#T3){ref-type="table"}) and six (table [4](#T4){ref-type="table"}).

###### 

(corrected table four) COX-2 expression in neoplastic and normal tissue

  Tissue type         Number of cases   COX-2   Positive rate(%)   P value   
  ------------------- ----------------- ------- ------------------ --------- ---------
  Neoplastic tissue   50                45      5                  90        0.000\*
  Normal tissue       6                 0       6                  0         

P \< 0.05

###### 

(corrected table five) COX-2 expression in tumor and paracancerous tissue

  Tissue type            Number of cases   COX-2   Positive rate(%)   P value   
  ---------------------- ----------------- ------- ------------------ --------- ---------
  Neoplastic tissue      50                45      5                  90        0.000\*
  Paracancerous tissue   7                 1       6                  14.3      

P \< 0.05

###### 

(corrected table six) 6 COX-2 expression and correlation with clinical features

  Clinical features                  COX-2   Positive expression rate   *P*value   
  ---------------------------------- ------- -------------------------- ---------- ---------
  Ages                                                                             0.599
  ≤60                                3       30                         90.90%     
  \> 60                              2       15                         88.20%     
  Sex                                                                              0.362
  Male                               4       27                         87.10%     
  Female                             1       18                         94.70%     
  Pathologic type                                                                  0.022\*
  Squamous carcinoma                 5       16                         76.20%     
  Adencarcinoma                      0       26                         100%       
  Mixed type                         0       3                          100%       
  Tumor length                                                                     0.518
  ≤3 cm                              2       14                         87.50%     
  \> 3 cm                            3       31                         91.20%     
  Level of Differentiation                                                         0.258
  Poor Differentiated                2       8                          80%        
  Moderate and Well Differentiated   3       37                         92.50%     
  TNM Stage                                                                        0.476
  I-II                               2       13                         86.70%     
  III-IV                             3       32                         91.40%     
  Lymph node                                                                       0.699
  N0                                 1       10                         90.90%     
  N1-3                               4       35                         89.70%     

\*P \< 0.05

Under the heading \"**Correlation of EGFR and COX-2 expression**\" The sentence reads: \"As shown in Table seven, no correlation was found between COX-2 and EGFR protein expression (**Χ**2 = 0.112, P = 0.555).\"

But should have read: \"As shown in Table seven, no correlation was found between COX-2 and EGFR protein expression (P \> 0.05).\"

Correct table seven (Table [5](#T5){ref-type="table"}).

###### 

(corrected table seven) Correlation of EGFR and COX-2 protein expression

                     EGFR   Total   
  ------- ---------- ------ ------- ----
  COX-2   negative   3      2       5
          positive   24     21      45
          Total      27     23      50

There was no significant relationship between COX-2 and EGFR. P \> 0.05.
